- Home
- ILPT vs OCGN Comparison
ILPT vs OCGN Comparison
Compare ILPT & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILPT | OCGN |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.3M | 387.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ILPT | OCGN |
|---|---|---|
| Price | $5.67 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 287.5K | ★ 3.1M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $445,459,000.00 | $5,370,000.00 |
| Revenue This Year | $3.00 | $32.40 |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.08 | ★ 14.26 |
| 52 Week Low | $2.45 | $0.52 |
| 52 Week High | $6.57 | $1.90 |
Technical Indicators
Market Signals| Indicator | ILPT | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 62.21 |
| Support Level | $5.54 | $1.18 |
| Resistance Level | $5.71 | $1.26 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 57.27 | 75.80 |
Price Performance
Historical ComparisonAbout ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").